PT  - JOURNAL ARTICLE
AU  - Azzam, Ahmed Y.
AU  - Morsy, Mahmoud M.
AU  - Ellabban, Mohamed Hatem
AU  - Morsy, Ahmed M.
AU  - Zahran, Adham Adel
AU  - Nassar, Mahmoud
AU  - Elsayed, Omar S.
AU  - Elswedy, Adam
AU  - Elamin, Osman
AU  - Al Zomia, Ahmed Saad
AU  - Abukhadijah, Hana J.
AU  - Alotaibi, Hammam A.
AU  - Atallah, Oday
AU  - Azab, Mohammed A.
AU  - Essibayi, Muhammed Amir
AU  - Dmytriw, Adam A.
AU  - Morsy, Mohamed D.
AU  - Altschul, David J.
TI  - Idiopathic Intracranial Hypertension and Cardiovascular Diseases Risk in the United Kingdom Women: An Obesity-Adjusted Risk Analysis Using Indirect Standardization
AID  - 10.1101/2024.10.20.24315837
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.20.24315837
4099  - http://medrxiv.org/content/early/2024/10/21/2024.10.20.24315837.short
4100  - http://medrxiv.org/content/early/2024/10/21/2024.10.20.24315837.full
AB  - Introduction Idiopathic intracranial hypertension (IIH) is associated with increased cardiovascular disease (CVD) risk, but the relative contributions of obesity versus IIH-specific factors remain unclear. This study aims to disentangle the effects of obesity and IIH on stroke and CVD risk, building upon previous research suggesting a two-fold increased risk of cardiovascular events in women with IIH compared to BMI-matched controls.Methods We conducted an obesity-adjusted risk analysis using Indirect Standardization analysis based on Adderley et al. study which utilized data from a cohort of 2,760 women with IIH and 27,125 matched healthy controls from The Health Improvement Network (THIN) database. We employed innovative statistical models to adjust for the confounding effects of obesity, estimating the risk of ischemic stroke and cardiovascular disease attributable to IIH independent of obesity. Four distinct models were used to elucidate the complex interrelationships between IIH, obesity, and CVD risk.Results Our analysis revealed that IIH confers additional cardiovascular risk beyond that attributed to obesity alone. Risk ratios for various cardiovascular outcomes were consistently elevated across models comparing IIH patients to controls within the same obesity strata. A striking synergistic effect between IIH and obesity was observed, with the composite CVD risk reaching a risk ratio of 6.19 (95% CI: 4.58-8.36, p<0.001) in obese IIH patients compared to non-obese controls.Conclusions This study provides compelling evidence for a nuanced relationship between IIH, obesity, and cardiovascular risk. IIH appears to confer substantial cardiovascular risk independent of obesity, necessitating a paradigm shift in IIH management to encompass comprehensive cardiovascular risk mitigation. Further research is needed to elucidate the underlying mechanisms and develop targeted interventions for this unique patient population.Competing Interest StatementDr. A.D. and our project are partially supported by the National Institute of Health (NIH) through NIH/NINDS grant R01NS076491.Funding StatementDr. A.D. and our project are partially supported by the National Institute of Health (NIH) through NIH/NINDS grant R01NS076491.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesN/A